HSTC HST Global, Inc.
HST Global (HSTC) news
HST Global, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker HSTC, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest HST Global news
We have not published a story on HST Global yet. When there is news, it will appear here.
HST Global annual financials
Questions about HST Global
What is the ticker symbol of HST Global?
HST Global, Inc. trades under the ticker HSTC on OTC.
Where is HST Global listed?
HST Global, Inc. is listed on OTC.
Which country or territory is HST Global listed under?
Our directory records HST Global, Inc. under United States.
Does aibio.space cover HST Global?
aibio.space lists HST Global, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
What was HST Global's revenue last year?
$0 for the fiscal year ended Dec 31, 2023, as reported to the SEC.
Is HST Global profitable?
HST Global, Inc. reported a net loss of $146,210 for the fiscal year ended Dec 31, 2023, and used $20,906 of cash in operations, per its annual report to the SEC.
How much cash does HST Global have?
$10,406 in cash at Sep 30, 2024, per its 10-Q.
Investor discussion: HST Global
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Stock chart
Listing details
- Company
- HST Global, Inc.
- Ticker
- HSTC
- Listing
- OTC
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio